Short description
Senzime develops unique patient-oriented monitoring systems that assess patients' biochemical and physiological processes.
Description
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Uppsala, Uppsala Lan, Sweden, Europe
Founded on
January 1, 1999
Exited on
January 30, 2018
Went public on
January 30, 2018
Stock symbol
SNZZF
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Blurry Noaccess
Sign in for full access